Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2015	Mar. 31, 2015
Current assets:
Cash	$ 331,069
Prepaid expenses and other current assets	27	$ 4
Deferred financing costs		1,104
Total current assets	331,096	1,108
Property, plant and equipment, net	16	9
Deferred tax assets	182
Total assets	331,294	1,117
Current liabilities:
Accounts payable	756	403
Due to Roivant Sciences Ltd. and Roivant Sciences, Inc.	1,629	2,307
Accrued legal fees	869	832
Accrued expenses	1,063	326
Income tax payable	252
Total current liabilities	4,569	3,868
Contingent payment liability	5,000	5,000
Total liabilities	$ 9,569	$ 8,868
Commitments and contingencies (Note I)
Shareholders' equity (deficit):
Common shares, par value $0.00001 per share, 1,000,000,000 shares authorized, 99,150,000 and 75,000,000 issued and outstanding at June 30, 2015 and March 31, 2015, respectively	$ 1	$ 1
Common shares subscribed	(1)	(1)
Additional paid-in capital	370,830	13,296
Accumulated deficit	(49,105)	(21,047)
Total shareholders' equity (deficit)	321,725	(7,751)
Total liabilities and shareholders' equity (deficit)	$ 331,294	$ 1,117